Oric Pharmaceuticals, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Oric Pharmaceuticals, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2018	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Research and development	19	22.8	35.9	56.9	61.7	85.2	114	110
General and administrative	3.35	5.73	13.4	22	25.1	25.6	28.8	33.2
Operating expenses	22.4	28.6	74.2	78.9	91.8	111	143	143
Operating income	-22.4	-28.6	-74.2	-78.9	-91.8	-111	-143	-143
Other non-operating income	1.01	1.69	0.48	0.16	2.65	10.1	15	13.5
Income tax	0	0	0	0	0	0	0	0
Net income	-21.4	-26.9	-73.7	-78.7	-89.1	-101	-128	-129
EBITDA	-21.5	-27.5	-73.2	-78	-90.8	-110	-142	-142
EPS, basic	-12.32	-14.15	-3.36	-2.07	-2.25	-1.96	-1.83	-1.47
EPS, diluted	-12.32	-14.15	-3.36	-2.07	-2.25	-1.96	-1.83	-1.47
Shares, basic (weighted)	1.73	1.9	21.9	38	39.7	51.5	69.7	87.8
Shares, diluted (weighted)	1.73	1.9	21.9	38	39.7	51.5	69.7	87.8

Balance sheet

	FY2018	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	42.6	89.2	78.4	226	66.8	23.4	59.4	45.7
Short-term investments			215	11	139	185	197	236
Other current assets		0.84	3.1	3.54	4.19	4.41	6.29	6.98
Total current assets		90	297	241	210	213	262	288
Property, plant and equipment		2.24	1.98	2.41	3.25	2.86	2.92	2.42
Lease right-of-use assets				11.8	11	9.14	8.38	6.66
Long-term investments			0	43.4	22	26.9	0	111
Other non-current assets		1.85	0.32	12.3	11.5	9.7	8.97	7.25
Total assets		94.1	299	299	247	252	274	409
Accounts payable		0.15	0.76	1.89	1.32	0.94	1.55	3.82
Accrued liabilities		5.2	8.25	13.3	14.1	19.5	23.3	16.6
Total current liabilities		5.35	9	15.2	15.4	20.5	24.8	20.4
Lease liabilities				10.5	9.44	7.46	6.17	4.11
Other non-current liabilities			0.22	10.5	9.44	7.46	6.17	4.11
Total liabilities		6.12	9.22	25.7	24.8	27.9	31	24.5
Total debt				10.5
Paid-in capital		2.61	456	518	558	659	806	1,076
Retained earnings		-92.7	-166	-245	-334	-435	-563	-692
Other comprehensive income			-0.03	-0.1	-1.29	0.26	0.38	0.79
Shareholders' equity	-64.4	-90.1	290	273	222	224	243	384
Total equity	-64.4	-90.1	290	273	222	224	243	384
Total liabilities and equity		94.1	299	299	247	252	274	409
Shares outstanding		1.98	36.7	39.4	45.1	54.9	71	98.5

Cash flow statement

	FY2018	FY2020	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-21.4	-26.9	-73.7	-78.7	-89.1	-101	-128	-129
Depreciation and amortization	0.9	1.03	0.97	0.9	0.97	1.03	1.11	1.22
Stock-based compensation	0.47	1.09	5.28	12.9	14.5	15.2	20.2	25
Change in payables	-0.41	0.99	4.3	2.93	-1.48	3.28	1.83	-7.25
Cash from operations	-20.7	-23.5	-45.3	-59.5	-75.1	-85.7	-113	-111
Capital expenditures	-0.53	-0.77	-0.67	-0.94	-2.08	-0.85	-1.19	-0.71
Purchases of investments			-225	-69.6	-238	-239	-252	-400
Sales and maturities of investments			10	229	131	197	275	253
Cash from investing	-0.51	-0.77	-216	158	-109	-43.4	22.1	-148
Stock issued	0.08	0.13	271	50	25	85	125	244
Cash from financing	38	70.8	251	49.1	25.2	85.7	127	245
Net change in cash	16.8	46.5	-10.7	148	-159	-43.4	36	-13.7
Free cash flow	-21.2	-24.3	-45.9	-60.5	-77.2	-86.5	-114	-112

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $9.35 on November 10, 2026.

Profitability

Metric	Value	How it is calculated
Return on equity (ROE)	-36.8%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-34.7%	Net income / average total assets.
Return on invested capital (ROIC)	-35.9%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.

Growth

Metric	Value	How it is calculated
Book value growth, 1y	58.1%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	20.0%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	5.8%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	49.2%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	18.3%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	6.5%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	25.9%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	30.3%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	32.0%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	13.2x	Current assets / current liabilities.
Quick ratio	12.8x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	12.8x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	5.8%	Total liabilities / total assets.
Working capital	$252.9M	Current assets - current liabilities.
Tangible book value	$381.3M	Shareholders' equity - goodwill - intangible assets.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$1.30	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share	-$1.04	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$1.03	Cash from operations / diluted weighted shares.
Book value per share	$3.68	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$3.68	Tangible book value / shares outstanding.
Cash per share	$2.55	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$968.6M	Share price x shares outstanding.
Enterprise value	$703.9M	Market cap + total debt - cash - short-term investments.
P/B	2.54x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	2.54x	Market cap / tangible book value, when positive.
FCF yield	-11.6%	Free cash flow / market cap.
Earnings yield	-14.5%	Net income / market cap (the inverse of P/E).

Was Oric Pharmaceuticals, Inc. profitable in fiscal 2025?

No. It reported a net loss of $129.5M.

How much free cash flow did Oric Pharmaceuticals, Inc. generate in fiscal 2025?

Cash from operations of $111.0M minus capital expenditures of $712.0K left free cash flow of -$111.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Oric Pharmaceuticals, Inc.